Leerink Partners Downgrades Humana (HUM) to Market Perform, 'Visibility into Recovery Diminished'

Leerink Partners analyst Whit Mayo downgraded Humana (NYSE: HUM) from Outperform to Market Perform with a price target of $250.00 (from $400.00).

The analyst comments "Downgrade HUM to Market Perform. Given the recently disclosed Stars headwinds for 2026, the lack of conviction we have in our recommendation, and inability to underwrite a reasonable path towards target margins, we move to a Market Perform rating that largely reflects our current thinking on the stock. We have ongoing concerns on elevated trend, heightened industry risks to 2H MLR estimates, and a continuation of broader challenges to the MA sector backdrop. Most positive readthrough is for UNH (OP), but acknowledge they may have some minor Stars challenges, as well."

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana closed at $279.45 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades BioMerieux (BIM:FP) (BMXMF) to Underweight
• Baird Downgrades Zions Bancorp (ZION) to Neutral
• UBS Upgrades Intermedia Capital Group (ICG:LN) (ICGUF) to Buy